title: Cellular immunity in recurrent vulvovaginal candidiasis.
abstract: Impaired T cell function has been reported to predispose women to recurrent vulvovaginal candidiasis, but conflicting results have been noted in the literature. Most clinical episodes occur in the late luteal phase, suggesting hormonal influence on host resistance. The present study assesses the cellular immune responses of 28 women with recurrent vaginal candidiasis (patients) and 25 control women (controls), noting results in relation to whether the women were in the follicular or luteal phase of the menstrual cycle at the time of sampling. Candida-stimulated peripheral blood lymphocyte proliferation was significantly reduced in patients compared with controls. Interferon-gamma (IFN-gamma) production in response to both Candida and purified protein derivative (PPD) stimulation was significantly lower in patients compared with controls. Skin test responses were comparable in both groups. A significant reduction in Candida-stimulated IFN-gamma production was seen in patients but not controls in the follicular phase compared with those in the luteal phase. There was also a trend towards lower proliferation in response to Candida in patients but not controls in the follicular phase compared with patients in the luteal phase. These results suggest that there is a partial T cell dysregulation in recurrent vaginal candidiasis which may be exacerbated by the hormonal balance present during the follicular phase, correlating with the risk of clinical infection.
authors.affiliation: Australian Institute of Mucosal Immunology, Newcastle, NSW.
authors.forename: E M
authors.initials: EM
authors.lastname: Corrigan
authors.forename: R L
authors.initials: RL
authors.lastname: Clancy
authors.forename: M L
authors.initials: ML
authors.lastname: Dunkley
authors.forename: F M
authors.initials: FM
authors.lastname: Eyers
authors.forename: K W
authors.initials: KW
authors.lastname: Beagley
mesh_terms: D000328:Adult; D000946:Antigens, Fungal / Q000276:immunology / Q000494:pharmacology; D002175:Candida / Q000276:immunology; D002181:Candidiasis, Vulvovaginal / Q000097:blood / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005498:Follicular Phase / Q000502:physiology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular / Q000276:immunology; D008183:Luteal Phase / Q000502:physiology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000946:Antigens, Fungal; D016207:Cytokines; D010835:Phytohemagglutinins